Jyong Biotech Ltd. (NASDAQ:MENS - Get Free Report)'s share price was up 10.5% during mid-day trading on Friday . The company traded as high as $44.59 and last traded at $43.76. Approximately 29,860 shares traded hands during mid-day trading, a decline of 86% from the average daily volume of 206,622 shares. The stock had previously closed at $39.59.
Wall Street Analyst Weigh In
Separately, Wall Street Zen upgraded Jyong Biotech to a "hold" rating in a research report on Monday, June 30th.
Get Our Latest Research Report on Jyong Biotech
Jyong Biotech Price Performance
About Jyong Biotech
(
Get Free Report)
OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers' health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.
Recommended Stories
Before you consider Jyong Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Jyong Biotech wasn't on the list.
While Jyong Biotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
